Posts tagged ‘Pharma CI’
October 15th, 2013
The annual Molecular Targets and Cancer Therapeutics meeting returns to Boston later this week and from the program and abstracts we’ve reviewed it looks like it will be an exciting meeting that will offer insights into many new cancer drugs in development.
Sally Church, PhD describes it as her favourite cancer meeting of the year. It’s a must attend for anyone in oncology new product development.
Jointly organized by AACR-EORTC-NCI, like the Ryder Cup it alternates between America and Europe. According to an AACR press release:
“The meeting, focusing on cancer drug development, draws nearly 3,000 attendees and gathers academics, scientists, and representatives from the pharmaceutical industry to discuss the effects new discoveries in cancer therapeutics and target selection have in molecular biology.”
You can read more coverage of the meeting on Biotech Strategy Blog.
September 18th, 2013
Next week sees the start of the 2013 European Cancer Congress in Amsterdam.
ECCO have announced that King Willem-Alexander of the Netherlands will attend the opening ceremony, which is impressive.
Now that most of the meeting abstracts are available online we are starting to focus on what data may be hot at the meeting.
On Pharma Strategy Blog Sally Church, PhD has published her ECCO 2013 preview of late-breaking abstracts and those on PI3-kinase.
In addition to updates on PD-1 and PD-L1 data presented at ASCO, those that have attracted her attention include:
- T-DM1 for HER-2+ metastatic breast cancer
- Exploratory biomarker observations from the BOLERO-3 trial
- FLT1 gene variation in NSCLC
- Long-term survival data for ipilimumab in unresectable melanoma.
The PI3K-AKT-mTOR pathway is dysregulated in 80% cancers and Sally says it’s one of her favorite pathways. Ph1/2 data will be presented on GDC-0032, a next generation PI3K inhibitor.
Preliminary data showing early promise for GDC-0032 in breast cancer was presented at the 2013 AACR annual meeting.
You can read more about what may be interesting at the 2013 European Cancer Congress on Biotech Strategy Blog. Check it out! If you have plans to be in Amsterdam we hope to see you there.
September 17th, 2013
Today, Biotech Strategy Blog launched a paywall where insights from cancer conferences will be available to subscribers who pay a fee for access. It’s the first in a series of online digital and print products that we will be launching in coming months.
The aim in setting up a paywall is to offer added value to a select group of readers. It’s no longer sustainable to generate quality content for free. Many online media outlets have already come to the same conclusion.
In the next three months, premium content subscribers on Biotech Strategy Blog will gain access to exclusive coverage from the European Cancer Congress in Amsterdam, AACR Molecular Targets Meeting in Boston and ASH annual meeting in New Orleans. We will also be sharing insights from a series of interviews on the FDA Breakthrough Therapy Designation.
We hope that the financial support of blog readers will allow coverage of more cancer meetings in 2014. It’s an exciting time to be at the vanguard of online media, and many are watching our new business model with baited breath as to whether they should move in this direction too…we expect they will join us before too long, it’s a matter of economics.
— Don Shimoda (@zDonShimoda) September 17, 2013
February 20th, 2013
Tumor Lysis Syndrome (TLS) has been in the news recently as a result of two patient deaths in a chronic lymphocytic leukemia (CLL) clinical trial with AbbVie’s ABT-199, a novel BCL-2 inhibitor in early stages of development.
What is TLS and why is this important in cancer research was subsequently analyzed by Icarus Consultants hematology industry expert, Sally Church, PhD on Pharma Strategy Blog.
Sally notes in her post, “we don’t yet know whether the effect in ABT-199 is a dose-schedule issue or a compound structure issue (especially given the reformulation from the original navitoclax issue).”
It’s a major setback to AbbVie ($ABBV) when the company was poised to start a phase 3 clinical trial with ABT-199 in CLL.
AbbVie will have to convince doctors that careful dose scheduling can solve the problem of a drug that may be too potent for the body to handle. Further deaths due to TLS could easily stop the development of this compound.
The setback to ABT-199 is, however, good news for ibrutinib that along with ABT-199 is in a race to market in CLL.
On February 12, 2013, ibrutinib received “breakthrough designation” from the FDA for the treatment of mantle cell lymphoma (MCL) and Waldenstrom’s macroglobulinemia.
Breakthrough designation means that a drug can be approved on the basis of early clinical data. Depending on when filing takes place, FDA approval of ibrutinib in MCL could be forthcoming later this year.
We expect to be producing a report on the CLL new products in development soon. This will cover some of the challenges and issues companies are facing. If you haven’t already done so, please sign up below if you would like to receive news alerts and be the first to know when reports are available.
January 28th, 2013
Making sense of data is what we do. We live in a world where, thanks to the internet, the sheer volume of available data is increasing at an enormous rate.
Too often we see staff at client companies focus their energy on gathering data as cheaply as possible, instead of asking or seeking to understand what does all the data mean from a competitive stand point?
Data is now commoditized. Anyone can gain access to past ASCO Virtual Meetings, for example, and watch a rerun of conference presentations. While obtaining data is relatively easy, insights are a lot more expensive and difficult to generate.
Well, they require the application of knowledge, deep understanding and expertise of the topic to analyze, conceptualize and visualize data, and then extrapolate what it means to a company or product.
Here’s a fun video that shows how a picture tells a thousand words. Professor Hans Rosling, in this excerpt from a BBC documentary, shows the public health history of 200 countries in 4 minutes…
Turning data into a powerful illustration requires the expenditure of intellectual effort.
Making sense of data is what we do at Icarus Consultants.
November 29th, 2012
Multiple Myeloma (MM) is forecast to be a hot topic at the forthcoming annual meeting of the American Society of Hematology (ASH) that starts in Atlanta next week.
There are four “Super Friday” satellite symposia and over 700+ MM abstracts that will be presented in multiple oral and poster sessions. If you add in the recent FDA approval for carfilzomib (Kyprolis) and the anticipation that pomalidomide (Actimid) will be approved soon, there’s a lot going on.
We specialize in Thought Leader or Key Opinion Leader (KOL) market research. Often projects are a hybrid where we discuss high-level strategic issues with KOLs and ask community hematology-oncologists or medical oncologists more practice-focused questions.
Based on our experience, multiple myeloma is a challenging topic for pharma market research:
- Treatment regimens can be complex, even some community medical oncologists have told us they are challenged by them.
- Treatment decisions are multifactorial and individualized, so it’s often hard for community based physicians to generalize.
- High prescribing community physicians may be in small towns not near a market research facility, requiring telephone interviews.
- Thought leaders are busy people – you need to focus on a few key questions you want them to answer.
- Access to top-tier thought leaders is difficult, they often will only talk to people they know or have met at medical or scientific meetings.
If you have plans to be in Atlanta for ASH, do contact us. We’d welcome the opportunity to meet up and tell you more about what we do.
October 29th, 2012
The 2012 Chemotherapy Foundation Symposium takes place at the Marriott Marquis in Times Square, New York City from November 7 – 10. Fortunately, the timing avoids the disruption expected this week from Hurricane Sandy.
The Greenspan Meeting as it’s also known (in recognition of the late Ezra M. Greenspan MD, the symposium founder) provides the opportunity for oncologists to learn about new developments in cancer therapy.
It is a joint presentation by the Mount Sinai School of Medicine and the non-profit Chemotherapy Foundation.
Sally Church, PhD who frequently attends says she particularly “enjoys the lectures that give a broad strategic overview of a particular topic.”
There’s usually a good turnout from the NJ/NY pharma industry and it’s interesting to talk to local academic and community oncologists about their practice.
You can read more about last year’s prostate cancer session at the 2011 Chemotherapy Foundation Symposium on Biotech Strategy Blog. The informative sessions cover a lot of ground and are well worth attending.
Update November 1, 2012 – Symposium not cancelled after Storm Sandy
Good to see The Chemotherapy Foundation announce on twitter today that the symposium will go on as scheduled. Hopefully the transport network will have some semblance of normality by then otherwise it will remain a challenge for many in the local area to attend.
The Chemotherapy Foundation Symposium will go on as scheduled. You can still register on chemotherapyfoundationsymposium.org
— Chemo Fdtn Symposium (@tcfsymposium) November 1, 2012
August 20th, 2012
To better showcase our pharmaceutical marketing strategy, KOL market research, new product development and competitive intelligence services we have recently upgraded the Icarus Consultants website.
Thanks to The Theme Foundry who provided outstanding customer service.
We hope that you like the new/look feel, particularly the homepage that combines company news, information on our services and why you should consider working with us.
Some of the new features you will see include:
- Video on the Homepage: we plan to change this regularly. At the moment it features a preview of ASCO 2012.
- New page with Case Studies. Client confidentiality prohibits us from saying too much, but we’ve attempted to give a flavor of some of our recent projects.
- Responsive theme: the site is now optimized for viewing on tablets and mobile devices.
If you have any comments about our new look or would like to learn more about our services, please contact us.
August 6th, 2012
When the dog days of summer and the Olympics are over, the normal rhythm of pharma marketing and new product development life continues with the major medical congresses and scientific meetings that take place in the Autumn/Fall.
A few of the meetings we will be attending and ones to watch out for include:
ESMO 2012 Congress, Vienna (#ESMO12) 28 September – 2 October, 2012
Building on the highly successful European Multidisciplinary Cancer Congress held in Stockholm last year, we expect the 2012 Congress of the European Society of Medical Oncology (ESMO) to be an exciting meeting.
ESMO have already announced that abstract submissions are up 30%. We expect a lot of interesting new data to be presented in Vienna, especially in light of the fact that the deadline for presentation at ASCO in June was very early this year. If you are interested in attending, the late registration deadline is August 22nd.
NYAS Pancreatic Cancer: Translation of New Ideas, New York, 12 October, 2012
For those interested in pancreatic cancer and insights into some of the preclinical and translational research that is being done with targeted drugs, a half-day meeting at The New York Academy of Sciences (NYAS) looks worth attending.
The keynote speaker is Dafna Bar-Sagi, PhD, Professor and Vice Dean for Science at the NYU Langone Medical Center. Icarus Consultants is pleased to be a promotional partner for the event. The inexpensive registration fee for nonmembers is only $40, with a networking reception to follow.
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin 6 – 9 November, 2012
Hosted by the European Organization for Research and Treatment (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR), this symposium is one of Sally Church’s favorite meetings of the year, with its focus on innovation in drug development, target selection and new products.
We hope to see you in Vienna, New York or Dublin!
May 15th, 2012
The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) takes place in Chicago in just over two weeks time from June 1 – 5. The ASCO abstracts will be publicly available tomorrow (May 16) at 6pm EDT.
We’re looking forward to being at ASCO, and picking up the latest data for new products and evaluating the impact this may have on our understanding of key pathways and drug development targets.
If you want to know what Sally Church, PhD predicts will be highlights of the ASCO 2012 meeting (in the absence of any abstract information) then watch her informative video and check out her ASCO preview post on Pharma Strategy Blog.
If you plan to be at ASCO 2012 and would like to meet up and discuss our capabilities, please contact us.